Africa's Big Pharma Market To Be Worth $45bn By 2020

By Admin
Follow @HealthCareG Big Pharma Companies Investing In Africa Include Sanofi, Novartis and GSK Rise Of Chronic Diseases Increases Demand For Wester...

 

  • Big Pharma Companies Investing In Africa Include Sanofi, Novartis and GSK
  • Rise Of Chronic Diseases Increases Demand For Western Drugs
  • Emerging Middle Class In Africa Sparks Pharma Growth

Recent reports suggest that big pharmaceutical companies are setting their sights on the African continent. The continent’s economic growth has been grabbing headlines in recent months and consequently Africa’s middle class has been emerging. Team this with the rise in chronic diseases and big pharma companies are taking interest.

The opportunity for pharmaceutical giants in Africa is forecasted to be worth an astonishing $45 billion by 2020 and the continent is expected to see a growth rate of 10.6 percent per annum, which puts it in line with growth in Latin America. This expected progression also makes Africa an exciting prospect for pharma companies, owing to the fact that more established emerging markets are seeing a slow-down in growth.

“We're thinking hard about what happens when those emerging starts start to slow because they are not going to continue growing at the rate that they're growing forever - and a place where we're putting a lot of our attention is Africa,” confirmed Novartis CEO Joe Jimenez.

European drug makers - including GlaxoSmithKline, Sanofi and Novartis - are investing in Africa to capture their share of the larger market. Sanofi is spending €70 million ($94.15 million) on a new plant in Algeria, while GSK just spent $98 million to raise its stake in its Nigerian consumer products unit. GSK is also working to boost its market penetration in other countries, with the goal of increasing volumes fivefold within five years, partly by keeping prices very low.

Source: Reuters

Share

Featured Articles

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Becton Dickinson – a major supplier of syringes – said it has upped manufacturing in its US facilities after FDA warning on China-made products

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma

Eli Lilly and Amazon Pharmacy Partner on Drugs Delivery

Digital Healthcare